A Naturalistic Evaluation of Extended-Release Naltrexone in Clinical Practice in Missouri.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Substance Abuse Treatment

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jsat.2016.07.014PMID 27692188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Principles of Drug Addiction Treatment: A Research-Based Guide (Third Edition)

  2018cited by this paper
• Extended-Release Naltrexone for Alcohol and Opioid Problems in Missouri Parolees and Probationers.

  2015cited by this paper
• A Phase 4, Pilot, Open-Label Study of VIVITROL® (Extended-Release Naltrexone XR-NTX) for Prisoners.

  2015cited by this paper
• Extended-release naltrexone for opioid relapse prevention among opioid-dependent, criminal justice-involved adults

  2015cited by this paper
• Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.

  2014cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2014cited by this paper
• Estimating the efficacy of Alcoholics Anonymous without self-selection bias: an instrumental variables re-analysis of randomized clinical trials.

  2014cited by this paper
• A tutorial on propensity score estimation for multiple treatments using generalized boosted models

  2013cited by this paper
• Financial Factors and the Implementation of Medications for Treating Opioid Use Disorders

  2012cited by this paper
• A Multisite Pilot Study of Extended-Release Injectable Naltrexone Treatment for Previously Opioid-Dependent Parolees and Probationers

  2012cited by this paper
• Oral naltrexone maintenance treatment for opioid dependence.

  2011cited by this paper
• Adoption and Implementation of Medications in Addiction Treatment Programs

  2011cited by this paper
• Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial.

  2011cited by this paper
• Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.

  2011cited by this paper
• The efficacy of disulfiram for the treatment of alcohol use disorder.

  2011cited by this paper
• Cost and utilization outcomes of opioid-dependence treatments.

  2011cited by this paper
• Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.

  2011cited by this paper
• Open-Label Pilot Study of Extended-Release Naltrexone to Reduce Drinking and Driving Among Repeat Offenders

  2011cited by this paper
• Extended-release naltrexone for alcohol dependence: persistence and healthcare costs and utilization.

  2011influential reference
• The Multiple Propensity Score as Control for Bias in the Comparison of More Than Two Treatment Arms: An Introduction From a Case Study in Mental Health

  2010cited by this paper
• Impact of Treatment With Intramuscular, Injectable, Extended-Release Naltrexone on Counseling and Support Group Participation in Patients With Alcohol Dependence

  2010cited by this paper
• Acamprosate for alcohol dependence

  2010influential reference
• Analysis of Observational Health Care Data Using SAS

  2010cited by this paper
• Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

  2009cited by this paper
• Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization.

  2008cited by this paper
• Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.

  2008cited by this paper
• Goodness‐of‐fit diagnostics for the propensity score model when estimating treatment effects using covariate adjustment with the propensity score

  2008influential reference
• A comparison of propensity score methods: a case‐study estimating the effectiveness of post‐AMI statin use

  2006cited by this paper
• Efficacy and Tolerability of Long-Acting Injectable Naltrexone for Alcohol Dependence: A Randomized Controlled Trial

  2005cited by this paper
• Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence.

  2002cited by this paper

• Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis.

  2025cites this paper
• Remission rates of patients with opioid use disorder who got naltrexone implantation: A retrospective study

  2024cites this paper
• Is extended release naltrexone superior to buprenorphine-naloxone to reduce drinking among outpatients receiving treatment for opioid use disorder? A secondary analysis of the CTN X:BOT trial.

  2021cites this paper
• Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone

  2020cites this paper
• Endogenous Opiates and Behavior: 2017.

  2019cites this paper
• A Systematic Review of the Effectiveness of Buprenorphine for Opioid Use Disorder Compared to Other Treatments: Implications for Research and Practice

  2019influential citation
• Adherence to extended release naltrexone: Patient and treatment characteristics

  2018cites this paper
• Long-acting intramuscular naltrexone for opioid use disorder: Utilization and association with multi-morbidity nationally in the Veterans Health Administration.

  2018cites this paper
• The effectiveness, safety and feasibility of extended-release naltrexone in treatment of opioid dependence: A 12-month clinical study

  2018cites this paper
• Pharmacotherapy for opioid addiction in community corrections

  2018cites this paper
• Suboxone: Rationale, Science, Misconceptions.

  2018cites this paper
• Extended‐release injectable naltrexone for opioid use disorder: a systematic review

  2018cites this paper
• Italian psychiatry

  2018cites this paper
• Predictors of induction onto extended-release naltrexone among unemployed heroin-dependent adults.

  2018cites this paper
• Effectiveness, safety and feasibility of extended‐release naltrexone for opioid dependence: a 9‐month follow‐up to a 3‐month randomized trial

  2018cites this paper